Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 4,847,979 shares, an increase of 11.4% from the January 31st total of 4,350,894 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 674,296 shares, the days-to-cover ratio is currently 7.2 days.
An institutional investor recently bought a new position in Protalix Biotherapeutics stock. Opaleye Management Inc. bought a new stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned 1.27% of Protalix Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.
Protalix Biotherapeutics (PLX) traded down $0.01 during trading hours on Tuesday, reaching $0.66. 313,427 shares of the company’s stock were exchanged, compared to its average volume of 876,162. The firm has a market cap of $326.91, a P/E ratio of -0.33 and a beta of 1.02. Protalix Biotherapeutics has a twelve month low of $0.48 and a twelve month high of $1.51.
Protalix Biotherapeutics Company Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.